Brian Piekos

Brian Piekos

Director of Finance/CFO at KALVISTA PHARMACEUTICALS, INC.

Net worth: 582 031 $ as of 31/05/2026

51 year
Health Technology
Consumer Services

Profile

Brian Piekos currently works at KalVista Pharmaceuticals, Inc., as Chief Financial & Accounting Officer from 2024.
Mr. Piekos also formerly worked at Cubist Pharmaceuticals LLC, as Senior Director-Corporate Finance, Tax & Treasury from 2010 to 2015, AMAG Pharmaceuticals, Inc., as Treasurer, Chief Financial & Accounting Officer in 2020, scPharmaceuticals, Inc., as Chief Financial Officer, Gemini Therapeutics, Inc., as Chief Financial & Accounting Officer in 2021, and Elicio Therapeutics, Inc., as Chief Financial Officer & Treasurer.
Mr. Piekos received his undergraduate degree from Ithaca College, graduate degree from UMass Chan Medical School, and Masters Business Admin degree from the University of Rochester Simon Business School.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
22/05/2026 21,661 ( 0.04% ) 582 031 $ 31/05/2026

Brian Piekos active positions

CompaniesPositionStart
KALVISTA PHARMACEUTICALS, INC. Director of Finance/CFO 09/09/2024

Former positions of Brian Piekos

CompaniesPositionEnd
ELICIO THERAPEUTICS, INC. Director of Finance/CFO 06/09/2024
GEMI THER Director of Finance/CFO 29/12/2022
AMAG PHARMACEUTICALS, INC. Director of Finance/CFO 01/12/2020
CUBIST PHARMACEUTICALS INC Comptroller/Controller/Auditor 01/02/2015
SCPHARMACEUTICALS INC. Director of Finance/CFO -
See the detail of Brian Piekos's experience

Training of Brian Piekos

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

58

1st degree connections

9

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies9

Health Technology

Consumer Services

Health Technology

Consumer Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!